Last reviewed · How we verify
NL005 High Dose
At a glance
| Generic name | NL005 High Dose |
|---|---|
| Also known as | NL005（ High Dose） |
| Sponsor | Beijing Northland Biotech. Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Efficacy and Safety Study of Thymosin Beta 4 in Patients With Acute Myocardial Infarction (PHASE2)
- Safety and Efficacy Study of Thymosin Beta 4 in Patients With Acute Myocardial Infarction.Infarction (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- NL005 High Dose CI brief — competitive landscape report
- NL005 High Dose updates RSS · CI watch RSS
- Beijing Northland Biotech. Co., Ltd. portfolio CI